The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs).
 
Hiroki Sato
No Relationships to Disclose
 
Daisuke Kubota
No Relationships to Disclose
 
Paul K. Paik
Honoraria - AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Celgene; EMD Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Celgene; EMD Serono; Takeda
Research Funding - Celgene; EMD Serono
Travel, Accommodations, Expenses - EMD Serono
 
Huan Qiao
No Relationships to Disclose
 
Achim A Jungbluth
Patents, Royalties, Other Intellectual Property - I receive royalties and own IP for several monoclonal antibodies developed during my time at the Ludwig Institute for Cancer Research (LICR) and MSKCC. I receive royalties from LICR and MSKCC, not from any company!
 
Natasha Rekhtman
No Relationships to Disclose
 
Adam Jacob Schoenfeld
No Relationships to Disclose
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma
 
Gregory J. Riely
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
Other Relationship - Pfizer; Roche/Genentech; Takeda
 
Christine Marie Lovly
Honoraria - Achilles Therapeutics; ARIAD; AstraZeneca; Blueprint Medicines; Cepheid; Foundation Medicine; Genentech; Genoptix; Lilly; Novartis; Pfizer; Sequenom; Takeda
Consulting or Advisory Role - Achilles Therapeutics; ARIAD; AstraZeneca; Blueprint Medicines; Cepheid; Foundation Medicine; Foundation Medicine; Genoptix; Novartis; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Novartis; Xcovery
Travel, Accommodations, Expenses - ARIAD; Cepheid; Foundation Medicine; Genoptix; Novartis; Pfizer; Sequenom; Takeda
 
Marc Ladanyi
Honoraria - Merck (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck (I); NCCN/AstraZeneca; Takeda
Research Funding - Helsinn Therapeutics; Loxo (Inst)
 
Pang-Dian Fan
No Relationships to Disclose